Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium

Herve Delacour, Sofya Lushchekina, Isabelle Mabboux, Franck Ceppa, Patrick Masson, Lawrence M Schopfer, Oksana Lockridge

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivarcurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of mivacurium leading to the discovery of a novel BCHE variant (c.185C>T, p.Ala34Val). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation remote from the active center determines the "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with a heterozygous enzyme of type atypical/silent. Kinetic analysis with succinyldithiocholine (SCdTC) as the substrate showed that Ala34Val BChE was inactive against this substrate. However, with BTC, the mutant enzyme was active, displaying an unexpected activation by excess substrate. Competitive inhibition of BTC by mivacurium gave a Ki = 1.35 mM consistent with the lack of activity with the related substrate SCdTC, and with the clinical data. Molecular dynamic simulations revealed the mechanism by which mutation Ala34Val determines the silent phenotype: a chain of intramolecular events leads to disruption of the catalytic triad, so that His438 no longer interacts with Ser198, but instead forms hydrogen bonds either with residues Glu197 and Trp82, or peripheral site residue Tyr332. However, at high BTC concentration, initial binding of substrate to the peripheral site triggers restoration of a functional catalytic triad, and activity with BTC.

Original languageEnglish (US)
Pages (from-to)476-483
Number of pages8
JournalBiochemical Pharmacology
Volume92
Issue number3
DOIs
StatePublished - Dec 1 2014

Fingerprint

Butyrylthiocholine
Butyrylcholinesterase
Point Mutation
Substrates
Molecular Dynamics Simulation
Mutation
Benzoylcholine
Molecular dynamics
Dibucaine
Phenotype
Neuromuscular Blockade
Succinylcholine
Kinetics
Apnea
Enzymes
Fluorides
Restoration
Muscle
Hydrogen
Hydrogen bonds

Keywords

  • Butyrylcholinesterase deficiency
  • Genetic diagnosis

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium. / Delacour, Herve; Lushchekina, Sofya; Mabboux, Isabelle; Ceppa, Franck; Masson, Patrick; Schopfer, Lawrence M; Lockridge, Oksana.

In: Biochemical Pharmacology, Vol. 92, No. 3, 01.12.2014, p. 476-483.

Research output: Contribution to journalArticle

Delacour, Herve ; Lushchekina, Sofya ; Mabboux, Isabelle ; Ceppa, Franck ; Masson, Patrick ; Schopfer, Lawrence M ; Lockridge, Oksana. / Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium. In: Biochemical Pharmacology. 2014 ; Vol. 92, No. 3. pp. 476-483.
@article{a0d2cfac893e406387ce92f1217c0937,
title = "Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), {"}silent{"} with mivacurium",
abstract = "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivarcurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of mivacurium leading to the discovery of a novel BCHE variant (c.185C>T, p.Ala34Val). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation remote from the active center determines the {"}silent{"} phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with a heterozygous enzyme of type atypical/silent. Kinetic analysis with succinyldithiocholine (SCdTC) as the substrate showed that Ala34Val BChE was inactive against this substrate. However, with BTC, the mutant enzyme was active, displaying an unexpected activation by excess substrate. Competitive inhibition of BTC by mivacurium gave a Ki = 1.35 mM consistent with the lack of activity with the related substrate SCdTC, and with the clinical data. Molecular dynamic simulations revealed the mechanism by which mutation Ala34Val determines the silent phenotype: a chain of intramolecular events leads to disruption of the catalytic triad, so that His438 no longer interacts with Ser198, but instead forms hydrogen bonds either with residues Glu197 and Trp82, or peripheral site residue Tyr332. However, at high BTC concentration, initial binding of substrate to the peripheral site triggers restoration of a functional catalytic triad, and activity with BTC.",
keywords = "Butyrylcholinesterase deficiency, Genetic diagnosis",
author = "Herve Delacour and Sofya Lushchekina and Isabelle Mabboux and Franck Ceppa and Patrick Masson and Schopfer, {Lawrence M} and Oksana Lockridge",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.bcp.2014.09.014",
language = "English (US)",
volume = "92",
pages = "476--483",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium

AU - Delacour, Herve

AU - Lushchekina, Sofya

AU - Mabboux, Isabelle

AU - Ceppa, Franck

AU - Masson, Patrick

AU - Schopfer, Lawrence M

AU - Lockridge, Oksana

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivarcurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of mivacurium leading to the discovery of a novel BCHE variant (c.185C>T, p.Ala34Val). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation remote from the active center determines the "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with a heterozygous enzyme of type atypical/silent. Kinetic analysis with succinyldithiocholine (SCdTC) as the substrate showed that Ala34Val BChE was inactive against this substrate. However, with BTC, the mutant enzyme was active, displaying an unexpected activation by excess substrate. Competitive inhibition of BTC by mivacurium gave a Ki = 1.35 mM consistent with the lack of activity with the related substrate SCdTC, and with the clinical data. Molecular dynamic simulations revealed the mechanism by which mutation Ala34Val determines the silent phenotype: a chain of intramolecular events leads to disruption of the catalytic triad, so that His438 no longer interacts with Ser198, but instead forms hydrogen bonds either with residues Glu197 and Trp82, or peripheral site residue Tyr332. However, at high BTC concentration, initial binding of substrate to the peripheral site triggers restoration of a functional catalytic triad, and activity with BTC.

AB - Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivarcurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of mivacurium leading to the discovery of a novel BCHE variant (c.185C>T, p.Ala34Val). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation remote from the active center determines the "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with a heterozygous enzyme of type atypical/silent. Kinetic analysis with succinyldithiocholine (SCdTC) as the substrate showed that Ala34Val BChE was inactive against this substrate. However, with BTC, the mutant enzyme was active, displaying an unexpected activation by excess substrate. Competitive inhibition of BTC by mivacurium gave a Ki = 1.35 mM consistent with the lack of activity with the related substrate SCdTC, and with the clinical data. Molecular dynamic simulations revealed the mechanism by which mutation Ala34Val determines the silent phenotype: a chain of intramolecular events leads to disruption of the catalytic triad, so that His438 no longer interacts with Ser198, but instead forms hydrogen bonds either with residues Glu197 and Trp82, or peripheral site residue Tyr332. However, at high BTC concentration, initial binding of substrate to the peripheral site triggers restoration of a functional catalytic triad, and activity with BTC.

KW - Butyrylcholinesterase deficiency

KW - Genetic diagnosis

UR - http://www.scopus.com/inward/record.url?scp=84910642392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910642392&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2014.09.014

DO - 10.1016/j.bcp.2014.09.014

M3 - Article

C2 - 25264279

AN - SCOPUS:84910642392

VL - 92

SP - 476

EP - 483

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 3

ER -